Inhibrx Biosciences, Inc. announced updated clinical data on November 17, 2026, regarding ozekibart (INBRX-109) in combination with irinotecan and temozolomide (IRI/TMZ) for patients with relapsed or refractory Ewing sarcoma. The data will be presented at the Connective Tissue Oncology Society 2026 Annual Meeting.
As of the September 18, 2026 data cutoff, 60 patients were enrolled and treated with the combination, including 9 adolescent patients, with 22 patients remaining on active treatment. Among the 51 response-evaluable patients, the study demonstrated an overall response rate (ORR) of 62.7%. This figure includes 2 complete responses (CRs) and 30 partial responses (PRs). Additionally, 84.3% of response-evaluable patients experienced a measurable reduction in tumor size from baseline.
The Disease Control Rate (DCR) was reported at 86.3%, which includes the 43 patients with measurable reductions and 12 patients who achieved stable disease. The median progression-free survival (mPFS) was 6.0 months (95% CI: 4.6–7.4). The company noted that durable clinical benefit exceeding 6 months was observed in 18 patients, including one patient maintaining a partial response for more than two years.
In comparison to historical benchmarks for irinotecan and temozolomide alone—which typically yield an ORR of approximately 15% to 30% and a median progression-free survival of roughly 3 to 4 months—the combination showed a marked improvement. The safety profile was described as acceptable and manageable, consistent with the known cytotoxic toxicities of IRI/TMZ and DR5 agonism, with no evidence of unexpected cumulative hepatotoxicity.
Separately, Inhibrx stated that the FDA has accepted for filing a biologics license application for ozekibart in conventional chondrosarcoma.